<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03823144</url>
  </required_header>
  <id_info>
    <org_study_id>18-010370</org_study_id>
    <nct_id>NCT03823144</nct_id>
  </id_info>
  <brief_title>Intravital Microscopy in Human Solid Tumors</brief_title>
  <official_title>Intravital Microscopy (IVM) in Human Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the tumor-associated vasculature of patients with solid tumors.&#xD;
      The investigators will use a technology known as intravital microscopy (IVM) in order to&#xD;
      visualize in real-time the vessels associated with solid tumors. The IVM observations may&#xD;
      determine if an individual patient's tumor vessels would be amenable to receiving systemic&#xD;
      therapy, based on the functionality of the vessels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective(s): To determine the feasibility and clinical utility of performing HIVM in&#xD;
      patients with solid tumors during standard course of treatment (surgical resection).&#xD;
&#xD;
      Secondary objective(s):&#xD;
&#xD;
        1. Compare the microscopic observation of the tumor-associated vessels with normal tissue&#xD;
           (e.g. peritoneal surface) in each individual subject.&#xD;
&#xD;
        2. Correlate the microscopic observations of the tumor-associated vessels with pathologic&#xD;
           grade of tumor.&#xD;
&#xD;
        3. To correlate the microscopic observation of the microvasculature with tumor-specific and&#xD;
           overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open-label, non-randomized, single center, study of IVM observation in conjunction with fluorescein in subjects with solid tumors undergoing surgical resection.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>1. Tumor vessel identification (# tumor vessels visualized per high power field)</measure>
    <time_frame>12-15 minutes</time_frame>
    <description>Identify and measure vessels associated with solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2. Tumor vessel density (# tumor vessels per square cm area observed)</measure>
    <time_frame>12-15 minutes</time_frame>
    <description>Determine vessel density per 10x field</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3. Fluorescent dye uptake (# tumor vessels with fluorescent dye uptake and # tumor vessels without dye uptake)</measure>
    <time_frame>12-15 minutes</time_frame>
    <description>Visualize vital dye within the vessels (fluorescein)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>4. Tumor blood flow (velocity, mm/sec)</measure>
    <time_frame>12-15 minutes</time_frame>
    <description>Calculate the blood flow velocity of the vessels and tissue penetration of fluorescent dye as a marker of vessel permeability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5. Post-operative comparison of the microvasculature of tumor with normal tissue</measure>
    <time_frame>15-20 minutes</time_frame>
    <description>Post-operative comparison of the microvasculature of tumor with normal tissue (e.g. peritoneum) in each individual subject using vessel diameters, vessel density, detection of intravital dye and flow rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6. Post-operative correlation of the microvasculature with pathologic features of the tumor implants (i.e. tumor grade) at the time of the final pathology report (5-7 days after surgery).</measure>
    <time_frame>5-7 days</time_frame>
    <description>The investigators will determine if there is a correlation between the microvasculature with pathologic features of the tumor implants (i.e. tumor grade) at the time of the final pathology report (5-7 days after surgery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative correlation of the microscopic observation of the tumor microvasculature tumor-specific and overall survival.</measure>
    <time_frame>5 years</time_frame>
    <description>The investigators will determine if there is a correlation between the microscopic observation of the tumor microvasculature tumor-specific and overall survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with solid tumors during surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Human Intravital Microscopy</intervention_name>
    <description>Intravital microscopy (IVM) allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years of age.&#xD;
&#xD;
          2. ECOG Performance Status of ≤ 2.&#xD;
&#xD;
          3. Measurable tumor by direct visualization requiring surgical resection in the OR.&#xD;
&#xD;
          4. Tumor types of origin include gastric, pancreatic, hepatobiliary, colorectal, and&#xD;
             sarcoma. Tumors may be primary or metastatic to solid or hollow intra-abdominal&#xD;
             organs.&#xD;
&#xD;
          5. Subject must understand the investigational nature of this study and sign an&#xD;
             Independent Ethics Committee/Institutional Review Board approved written informed&#xD;
             consent.&#xD;
&#xD;
          6. Subject must have a skin prick test pre-operatively (at the time of the preoperative&#xD;
             visit and after signed informed consent for entry into this clinical trial is given)&#xD;
             to determine any sensitivity to fluorescein.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations.&#xD;
&#xD;
          2. Renal dysfunction as defined as a GFR &lt; 45.&#xD;
&#xD;
          3. Liver dysfunction as defined by Child-Pugh score &gt; 5, or LFT's 1.5x above normal&#xD;
             range.&#xD;
&#xD;
          4. Any known allergy or prior reaction to fluorescein or a positive skin prick test to&#xD;
             fluorescein.&#xD;
&#xD;
          5. Pregnant or nursing female subjects, determined preoperatively with a urine pregnancy&#xD;
             test.&#xD;
&#xD;
          6. Unwilling or unable to follow protocol requirements.&#xD;
&#xD;
          7. Any condition which in the Investigators' opinion deems the patient unsuitable (e.g.,&#xD;
             abnormal EKG, including T wave inversion, elevated T waves, prolonged QRS interval, or&#xD;
             conduction blocks) or that requires further work-up (including cardiac echo or stress&#xD;
             test).&#xD;
&#xD;
          8. Any condition that excludes surgery as the standard of care (e.g. high disease burden&#xD;
             where alternative treatments like systemic chemotherapy would be preferred).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel M Gabriel, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuel M Gabriel, M.D., Ph.D.</last_name>
    <phone>904-953-2523</phone>
    <email>gabriel.emmanuel@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael B Wallace, M.D.</last_name>
    <phone>904-953-2221</phone>
    <email>wallace.michael@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel M Gabriel, M.D., Ph. D.</last_name>
      <phone>904-953-2523</phone>
      <email>gabriel.emmanuel@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Emmanuel M Gabriel, M.D., Ph. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael B Wallace, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, Appenheimer MM, Vardam TD, Weis EL, Passanese J, Wang WC, Gollnick SO, Dewhirst MW, Rose-John S, Repasky EA, Baumann H, Evans SS. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest. 2011 Oct;121(10):3846-59. doi: 10.1172/JCI44952. Epub 2011 Sep 19.</citation>
    <PMID>21926464</PMID>
  </results_reference>
  <results_reference>
    <citation>Fisher DT, Muhitch JB, Kim M, Doyen KC, Bogner PN, Evans SS, Skitzki JJ. Intraoperative intravital microscopy permits the study of human tumour vessels. Nat Commun. 2016 Feb 17;7:10684. doi: 10.1038/ncomms10684.</citation>
    <PMID>26883450</PMID>
  </results_reference>
  <results_reference>
    <citation>Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. Semin Thromb Hemost. 2010 Apr;36(3):321-31. doi: 10.1055/s-0030-1253454. Epub 2010 May 20.</citation>
    <PMID>20490982</PMID>
  </results_reference>
  <results_reference>
    <citation>Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat. 2010 Feb-Apr;13(1-2):16-28. doi: 10.1016/j.drup.2009.12.001. Epub 2010 Jan 12.</citation>
    <PMID>20061178</PMID>
  </results_reference>
  <results_reference>
    <citation>Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation. 2010 Apr;17(3):206-25. doi: 10.1111/j.1549-8719.2010.00029.x.</citation>
    <PMID>20374484</PMID>
  </results_reference>
  <results_reference>
    <citation>Skitzki JJ, Chen Q, Wang WC, Evans SS. Primary immune surveillance: some like it hot. J Mol Med (Berl). 2007 Dec;85(12):1361-7. doi: 10.1007/s00109-007-0245-7. Epub 2007 Aug 18.</citation>
    <PMID>17704903</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer. 2002 Apr;2(4):266-76. doi: 10.1038/nrc778.</citation>
    <PMID>12001988</PMID>
  </results_reference>
  <results_reference>
    <citation>Murooka TT, Mempel TR. Multiphoton intravital microscopy to study lymphocyte motility in lymph nodes. Methods Mol Biol. 2012;757:247-57. doi: 10.1007/978-1-61779-166-6_16.</citation>
    <PMID>21909917</PMID>
  </results_reference>
  <results_reference>
    <citation>Entenberg D, Kedrin D, Wyckoff J, Sahai E, Condeelis J, Segall JE. Imaging tumor cell movement in vivo. Curr Protoc Cell Biol. 2013 Mar;Chapter 19:19.7.1-19.7.19. doi: 10.1002/0471143030.cb1907s58.</citation>
    <PMID>23456602</PMID>
  </results_reference>
  <results_reference>
    <citation>McLaughlin RA, Scolaro L, Robbins P, Hamza S, Saunders C, Sampson DD. Imaging of human lymph nodes using optical coherence tomography: potential for staging cancer. Cancer Res. 2010 Apr 1;70(7):2579-84. doi: 10.1158/0008-5472.CAN-09-4062. Epub 2010 Mar 16.</citation>
    <PMID>20233873</PMID>
  </results_reference>
  <results_reference>
    <citation>Patsialou A, Bravo-Cordero JJ, Wang Y, Entenberg D, Liu H, Clarke M, Condeelis JS. Intravital multiphoton imaging reveals multicellular streaming as a crucial component of in vivo cell migration in human breast tumors. Intravital. 2013 Apr 1;2(2):e25294. doi: 10.4161/intv.25294.</citation>
    <PMID>25013744</PMID>
  </results_reference>
  <results_reference>
    <citation>Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012 Jan 20;30(3):263-7. doi: 10.1200/JCO.2011.37.1039. Epub 2011 Dec 12.</citation>
    <PMID>22162570</PMID>
  </results_reference>
  <results_reference>
    <citation>Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D; French Surgical Association. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010 Dec 15;116(24):5608-18. doi: 10.1002/cncr.25356. Epub 2010 Aug 24.</citation>
    <PMID>20737573</PMID>
  </results_reference>
  <results_reference>
    <citation>Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dube P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010 Jan 1;28(1):63-8. doi: 10.1200/JCO.2009.23.9285. Epub 2009 Nov 16. Erratum In: J Clin Oncol. 2010 Apr 1;28(10):1808.</citation>
    <PMID>19917863</PMID>
  </results_reference>
  <results_reference>
    <citation>Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D; Association Francaise de Chirurgie. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010 Sep;17(9):2370-7. doi: 10.1245/s10434-010-1039-7. Epub 2010 Mar 25.</citation>
    <PMID>20336386</PMID>
  </results_reference>
  <results_reference>
    <citation>Kalogeromitros DC, Makris MP, Aggelides XS, Mellios AI, Giannoula FC, Sideri KA, Rouvas AA, Theodossiadis PG. Allergy skin testing in predicting adverse reactions to fluorescein: a prospective clinical study. Acta Ophthalmol. 2011 Aug;89(5):480-3. doi: 10.1111/j.1755-3768.2009.01722.x. Epub 2009 Nov 10.</citation>
    <PMID>19906081</PMID>
  </results_reference>
  <results_reference>
    <citation>Jaffer FA. Intravital fluorescence microscopic molecular imaging of atherosclerosis. Methods Mol Biol. 2011;680:131-40. doi: 10.1007/978-1-60761-901-7_9.</citation>
    <PMID>21153378</PMID>
  </results_reference>
  <results_reference>
    <citation>Munn LL, Padera TP. Imaging the lymphatic system. Microvasc Res. 2014 Nov;96:55-63. doi: 10.1016/j.mvr.2014.06.006. Epub 2014 Jun 21.</citation>
    <PMID>24956510</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolfe DR. Fluorescein angiography basic science and engineering. Ophthalmology. 1986 Dec;93(12):1617-20. doi: 10.1016/s0161-6420(86)33521-8.</citation>
    <PMID>3808620</PMID>
  </results_reference>
  <results_reference>
    <citation>Bloom JN, Herman DC, Elin RJ, Sliva CA, Ruddel ME, Nussenblatt RB, Palestine AG. Intravenous fluorescein interference with clinical laboratory tests. Am J Ophthalmol. 1989 Oct 15;108(4):375-9. doi: 10.1016/s0002-9394(14)73304-5.</citation>
    <PMID>2801858</PMID>
  </results_reference>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>March 24, 2023</last_update_submitted>
  <last_update_submitted_qc>March 24, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Emmanuel M. Gabriel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03823144/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03823144/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03823144
org study id: 18-010370
nct id: NCT03823144
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: Yes
This study will investigate the tumor-associated vasculature of patients with solid tumors.
      The investigators will use a technology known as intravital microscopy (IVM) in order to
      visualize in real-time the vessels associated with solid tumors. The IVM observations may
      determine if an individual patient's tumor vessels would be amenable to receiving systemic
      therapy, based on the functionality of the vessels.
Primary objective(s): To determine the feasibility and clinical utility of performing HIVM in
      patients with solid tumors during standard course of treatment (surgical resection).

      Secondary objective(s):

        1. Compare the microscopic observation of the tumor-associated vessels with normal tissue
           (e.g. peritoneal surface) in each individual subject.

        2. Correlate the microscopic observations of the tumor-associated vessels with pathologic
           grade of tumor.

        3. To correlate the microscopic observation of the microvasculature with tumor-specific and
           overall survival.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Diagnostic
masking: None (Open Label)
masking description: This is an open-label, non-randomized, single center, study of IVM observation in conjunction with fluorescein in subjects with solid tumors undergoing surgical resection.
measure: 1. Tumor vessel identification (# tumor vessels visualized per high power field)
time frame: 12-15 minutes
description: Identify and measure vessels associated with solid tumors
measure: 2. Tumor vessel density (# tumor vessels per square cm area observed)
time frame: 12-15 minutes
description: Determine vessel density per 10x field
measure: 3. Fluorescent dye uptake (# tumor vessels with fluorescent dye uptake and # tumor vessels without dye uptake)
time frame: 12-15 minutes
description: Visualize vital dye within the vessels (fluorescein)
measure: 4. Tumor blood flow (velocity, mm/sec)
time frame: 12-15 minutes
description: Calculate the blood flow velocity of the vessels and tissue penetration of fluorescent dye as a marker of vessel permeability.
measure: 5. Post-operative comparison of the microvasculature of tumor with normal tissue
time frame: 15-20 minutes
description: Post-operative comparison of the microvasculature of tumor with normal tissue (e.g. peritoneum) in each individual subject using vessel diameters, vessel density, detection of intravital dye and flow rates.
measure: 6. Post-operative correlation of the microvasculature with pathologic features of the tumor implants (i.e. tumor grade) at the time of the final pathology report (5-7 days after surgery).
time frame: 5-7 days
description: The investigators will determine if there is a correlation between the microvasculature with pathologic features of the tumor implants (i.e. tumor grade) at the time of the final pathology report (5-7 days after surgery).
measure: Post-operative correlation of the microscopic observation of the tumor microvasculature tumor-specific and overall survival.
time frame: 5 years
description: The investigators will determine if there is a correlation between the microscopic observation of the tumor microvasculature tumor-specific and overall survival.
arm group label: Arm 1
arm group type: Experimental
description: Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with solid tumors during surgical resection.
intervention type: Device
intervention name: Human Intravital Microscopy
description: Intravital microscopy (IVM) allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
arm group label: Arm 1
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Emmanuel M Gabriel, M.D., Ph.D.
role: Principal Investigator
affiliation: Mayo Clinic
last name: Emmanuel M Gabriel, M.D., Ph.D.
phone: 904-953-2523
email: gabriel.emmanuel@mayo.edu
last name: Michael B Wallace, M.D.
phone: 904-953-2221
email: wallace.michael@mayo.edu
facility: 
status: Recruiting
contact: 
investigator: 
investigator: 
country: United States
url: https://www.mayo.edu/research/clinical-trials
description: Mayo Clinic Clinical Trials
citation: Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, Appenheimer MM, Vardam TD, Weis EL, Passanese J, Wang WC, Gollnick SO, Dewhirst MW, Rose-John S, Repasky EA, Baumann H, Evans SS. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest. 2011 Oct;121(10):3846-59. doi: 10.1172/JCI44952. Epub 2011 Sep 19.
PMID: 21926464
citation: Fisher DT, Muhitch JB, Kim M, Doyen KC, Bogner PN, Evans SS, Skitzki JJ. Intraoperative intravital microscopy permits the study of human tumour vessels. Nat Commun. 2016 Feb 17;7:10684. doi: 10.1038/ncomms10684.
PMID: 26883450
citation: Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. Semin Thromb Hemost. 2010 Apr;36(3):321-31. doi: 10.1055/s-0030-1253454. Epub 2010 May 20.
PMID: 20490982
citation: Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat. 2010 Feb-Apr;13(1-2):16-28. doi: 10.1016/j.drup.2009.12.001. Epub 2010 Jan 12.
PMID: 20061178
citation: Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation. 2010 Apr;17(3):206-25. doi: 10.1111/j.1549-8719.2010.00029.x.
PMID: 20374484
citation: Skitzki JJ, Chen Q, Wang WC, Evans SS. Primary immune surveillance: some like it hot. J Mol Med (Berl). 2007 Dec;85(12):1361-7. doi: 10.1007/s00109-007-0245-7. Epub 2007 Aug 18.
PMID: 17704903
citation: Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer. 2002 Apr;2(4):266-76. doi: 10.1038/nrc778.
PMID: 12001988
citation: Murooka TT, Mempel TR. Multiphoton intravital microscopy to study lymphocyte motility in lymph nodes. Methods Mol Biol. 2012;757:247-57. doi: 10.1007/978-1-61779-166-6_16.
PMID: 21909917
citation: Entenberg D, Kedrin D, Wyckoff J, Sahai E, Condeelis J, Segall JE. Imaging tumor cell movement in vivo. Curr Protoc Cell Biol. 2013 Mar;Chapter 19:19.7.1-19.7.19. doi: 10.1002/0471143030.cb1907s58.
PMID: 23456602
citation: McLaughlin RA, Scolaro L, Robbins P, Hamza S, Saunders C, Sampson DD. Imaging of human lymph nodes using optical coherence tomography: potential for staging cancer. Cancer Res. 2010 Apr 1;70(7):2579-84. doi: 10.1158/0008-5472.CAN-09-4062. Epub 2010 Mar 16.
PMID: 20233873
citation: Patsialou A, Bravo-Cordero JJ, Wang Y, Entenberg D, Liu H, Clarke M, Condeelis JS. Intravital multiphoton imaging reveals multicellular streaming as a crucial component of in vivo cell migration in human breast tumors. Intravital. 2013 Apr 1;2(2):e25294. doi: 10.4161/intv.25294.
PMID: 25013744
citation: Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012 Jan 20;30(3):263-7. doi: 10.1200/JCO.2011.37.1039. Epub 2011 Dec 12.
PMID: 22162570
citation: Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D; French Surgical Association. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010 Dec 15;116(24):5608-18. doi: 10.1002/cncr.25356. Epub 2010 Aug 24.
PMID: 20737573
citation: Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dube P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010 Jan 1;28(1):63-8. doi: 10.1200/JCO.2009.23.9285. Epub 2009 Nov 16. Erratum In: J Clin Oncol. 2010 Apr 1;28(10):1808.
PMID: 19917863
citation: Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D; Association Francaise de Chirurgie. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010 Sep;17(9):2370-7. doi: 10.1245/s10434-010-1039-7. Epub 2010 Mar 25.
PMID: 20336386
citation: Kalogeromitros DC, Makris MP, Aggelides XS, Mellios AI, Giannoula FC, Sideri KA, Rouvas AA, Theodossiadis PG. Allergy skin testing in predicting adverse reactions to fluorescein: a prospective clinical study. Acta Ophthalmol. 2011 Aug;89(5):480-3. doi: 10.1111/j.1755-3768.2009.01722.x. Epub 2009 Nov 10.
PMID: 19906081
citation: Jaffer FA. Intravital fluorescence microscopic molecular imaging of atherosclerosis. Methods Mol Biol. 2011;680:131-40. doi: 10.1007/978-1-60761-901-7_9.
PMID: 21153378
citation: Munn LL, Padera TP. Imaging the lymphatic system. Microvasc Res. 2014 Nov;96:55-63. doi: 10.1016/j.mvr.2014.06.006. Epub 2014 Jun 21.
PMID: 24956510
citation: Wolfe DR. Fluorescein angiography basic science and engineering. Ophthalmology. 1986 Dec;93(12):1617-20. doi: 10.1016/s0161-6420(86)33521-8.
PMID: 3808620
citation: Bloom JN, Herman DC, Elin RJ, Sliva CA, Ruddel ME, Nussenblatt RB, Palestine AG. Intravenous fluorescein interference with clinical laboratory tests. Am J Ophthalmol. 1989 Oct 15;108(4):375-9. doi: 10.1016/s0002-9394(14)73304-5.
PMID: 2801858
responsible party type: Principal Investigator
investigator affiliation: Mayo Clinic
investigator full name: Emmanuel M. Gabriel
investigator title: Principal Investigator
mesh term: Neoplasms
sharing ipd: No
provided document: 
provided document: 